UAE Doctors Warn: Weight Loss with Injectable Drugs May Lead to Muscle Mass Loss, Not Just Fat
Read more
Khaleej Times
www.khaleejtimes.com

UAE Doctors Warn: Weight Loss with Injectable Drugs May Lead to Muscle Mass Loss, Not Just Fat

Although the goal of people resorting to popular injectable drugs for weight loss is often to reduce body mass, doctors from the United Arab Emirates warn that the number on the scale does not tell the whole story. Specialists note that when using medications such as Mounjaro, Ozempic, and Wegovy, patients should pay attention not only to excess fat but also to the loss of muscle tissue, which is critically important for maintaining strength, mobility, and long-term health.

Risks can increase in patients who significantly reduce food intake while taking these medications, especially if they suffer from protein deficiency, dehydration, or insufficient physical activity. The medical community emphasizes that the main objective should not just be rapid weight loss, but improving metabolic health while preserving muscle strength and physical functions.

Dr. Niyas Khalid, an internal medicine specialist at Burjeel Hospital in Abu Dhabi, stated: 'Never assess weight loss solely by the scale.' He clarified that before starting treatment, doctors conduct a comprehensive assessment of the patient's overall obesity profile, including metabolic status, relevant blood tests, nutritional status, and body composition.

'We collaborate closely with dietitians and nutritionists who assess body composition, often using bioelectrical impedance analysis (such as InBody) to determine fat and muscle mass. Periodic re-evaluations during treatment help us understand whether weight loss is primarily due to fat or includes excessive loss of muscle tissue. We also consider physical strength, functional capabilities, and weight loss rates,' added Dr. Khalid.

He also warned patients that rapid weight loss can be accompanied by muscle loss, especially with inadequate nutrition and physical activity. It is important to distinguish between fat loss and muscle mass loss, as the loss of muscle tissue can negatively affect physical functions, especially in the elderly and those already at risk of muscle weakness.

Dr. Amna Kiran, an endocrinologist at the International Modern Hospital in Dubai, reported that Mounjaro (tirzepatide), Ozempic, and Wegovy (semaglutide) are among the most common and recognized medications in the UAE, with Mounjaro being particularly popular due to its high effectiveness in weight loss. According to Dr. Kiran, 'an observational study in the UAE showed that Mounjaro accounted for 65.6 percent of GLP-1 based prescriptions in the studied cohort in 2024.'

However, she stressed that weight loss does not always indicate the amount of lost muscle mass, so adequate monitoring is necessary. In her regular practice, Dr. Kiran uses body weight measurement, waist circumference, and simple muscle function tests, including grip strength. While BIA can help track body composition trends, its accuracy depends on hydration and other factors. For a more precise assessment, especially in patients at risk of significant muscle loss, she prefers Dexa scanning.

Dr. Kiran also cited the results of the Surmount-1 subgroup study, which examined changes in body composition during tirzepatide treatment. 'The Surmount-1 subgroup study found that approximately 75 percent of the lost weight was fat mass, and 25 percent was muscle mass; importantly, muscle mass loss does not necessarily mean equivalent loss of skeletal muscle.' She explained that muscle mass includes more than just skeletal muscles, and measurements can be distorted by factors such as hydration levels. Therefore, doctors insist on interpreting body composition analysis results alongside clinical examinations, rather than equating every loss of muscle mass to a loss of muscle.

One of the mechanisms of action of these drugs is appetite suppression. Nevertheless, a significant reduction in food intake can make it difficult to meet the body's nutritional needs, especially if meals are skipped or consumption of protein-rich foods is ignored. Dr. Khalid noted that some patients eat significantly less than required, including protein deficiency, while others reduce fluid intake due to nausea or other gastrointestinal side effects.

He advised patients to include protein-rich foods in their diet, such as eggs, fish, lean meat, dairy products, and legumes, with individual nutrition plans developed after consulting with dietitians. Maintaining adequate hydration throughout the treatment course is also recommended. Protein and fluid needs vary depending on body composition, age, kidney function, and other clinical factors.

Furthermore, physical activity must become part of a structured weight management plan. The World Health Organization recommends at least 150 minutes of moderate physical activity per week, but these figures must be adapted to each patient's health condition and physical capabilities.

Dr. Kishan Delampadi, a consultant endocrinologist at NMC Royal Hospital Sharjah, stated that the growing popularity of these drugs should not dictate the decision to take them. He explained that these medications work by influencing appetite and satiety, helping people reduce their food intake. However, they are not suitable for everyone, and the choice depends on weight, medical history, existing conditions, medications being taken, and the person's treatment goals.

He also cautioned patients against using prescription drugs simply because someone they know achieved good results, emphasizing the need to differentiate between drugs approved for diabetes treatment and those intended for weight control. According to him, medical evaluation, a proper prescription, and regular monitoring are mandatory, and the medications should complement, not replace, a balanced diet, physical activity, and behavioral changes.

Dr. Delampadi added that side effects such as nausea, vomiting, diarrhea, or constipation can affect hydration and nutrient intake if they persist for a long time. This is especially important with age, as muscle mass and strength naturally decline. Rapid weight loss combined with poor nutrition and a sedentary lifestyle can complicate the maintenance of independence. Even young adults should take care of their muscles, rather than focusing solely on appearance or clothing size.

Similar stories

UAE Authorities Urge Residents to Report Drug Side Effects as Part of Medication Safety Campaign
Read more
www.khaleejtimes.com

UAE Authorities Urge Residents to Report Drug Side Effects as Part of Medication Safety Campaign

Residents of the United Arab Emirates (UAE) who suspect side effects after taking medications are strongly advised to report them to the relevant health authorities. This is part of a nationwide initiative aimed at enhancing medication safety levels.

The Emirates Drug Authority (EDA) has launched a campaign titled 'Speak Up .. Stay Safe.' This campaign is conducted in collaboration with five health authorities and calls on patients, caregivers, and healthcare professionals to share information about possible adverse reactions.

The campaign was announced on Wednesday, November 4th, and is part of the global MedSafetyWeek 2026, which runs from November 2nd to 8th. Authorities emphasized that reporting suspected side effects helps identify potential safety issues requiring further investigation, even if the drug has already received marketing approval.

Residents can use the EDA's DAWA intelligent tool to register suspected side effects of medicines and other medical products. This tool simplifies the process of submitting experiential information, after which reports are forwarded to specialists for assessment according to established procedures.

The tool was developed and approved through a partnership between EDA and the Uppsala Monitoring Centre and supports continuous monitoring of drugs available on the market. EDA also strongly recommended that patients, caregivers, and healthcare professionals utilize official reporting channels.

Dr. Ruqaiya Aqeel Al Bastaki, Executive Director of the Medical Products Regulatory Sector at EDA, noted that drug safety monitoring does not cease after a product receives approval and enters the market. She explained that responsibility remains throughout the entire lifecycle of the drug, as new information regarding its impact on patients continues to emerge.

Reports provided by residents and healthcare professionals are analyzed alongside other scientific data. This information allows authorities to identify potential danger signals that require deeper investigation. According to Al Bastaki, an effective drug safety control system depends on cooperation among regulatory bodies, healthcare professionals, pharmaceutical companies, patients, and caregivers.

She also stressed that reporting should become an integral part of responsible drug use, rather than being limited only to informational campaigns. The nationwide campaign unites EDA, the Ministry of Health and Prevention, the Emirates Health Services, Dubai Health Authority, Abu Dhabi Department of Health, and Sharjah Health Authority.

This year's MedSafetyWeek is running under the slogan: 'Don't Ignore Side Effects, Report Them!' This initiative, now in its 11th edition, is coordinated by the Uppsala Monitoring Centre in collaboration with drug regulators, monitoring centers, and international organizations.

As part of the campaign, virtual seminars will be organized for healthcare professionals to enhance their understanding of drug safety monitoring and managing suspected adverse effects. Awareness events will also take place at the University of Sharjah, where students will attend lectures on pharmacovigilance, the drug safety monitoring process, and receive training on using official reporting channels.

A dedicated webinar for pharmaceutical companies will explain their obligations and requirements for drug safety monitoring. This guide defines the responsibilities of relevant organizations and the requirements for monitoring safety information and managing risks associated with drugs after they have received marketing authorization.

NYU Abu Dhabi study shows economic benefits of weight-loss drugs like Wegovy and Ozempic
Read more
www.khaleejtimes.com

NYU Abu Dhabi study shows economic benefits of weight-loss drugs like Wegovy and Ozempic

According to a new study conducted by NYU Abu Dhabi, medications for diabetes treatment and weight management, including Ozempic and Wegovy, may bring economic benefits that extend beyond improving patient health. It was found that the use of these treatments is associated with increased employment and longer working hours.

Researchers used nationwide data from Denmark and found that people receiving treatment for type 2 diabetes were more likely to be employed, while those taking weight management drugs increased their working hours if they were already employed.

The study examined two drugs: semaglutide, marketed as Ozempic (for type 2 diabetes) and Wegovy (for weight control). Both medications belong to the GLP-1 receptor agonist class, which mimics the natural hormone regulating appetite and blood sugar levels.

The analysis was based on Danish population records from 2018 to 2024, examining changes in earnings, working hours, and employment before and after patients began therapy. Statistical methods were used to separate the effects of the treatment itself from general labor market changes.

Among patients receiving subsidized Ozempic treatment for diabetes, it was found that the therapy increased the probability of employment by 4.1 percentage points. Furthermore, this group demonstrated an increase in working hours by 19.5 hours per quarter.

However, the results were different for patients who self-paid for Wegovy to correct their weight. Although the drug did not lead to a significant increase in the probability of employment, those who were already employed increased their workload by an additional 29.7 hours per quarter.

Weda Narasimhan, Assistant Professor of Economics at NYU Abu Dhabi, noted that this data underscores the need to consider the broader economic impact of medications, not just the direct costs. She added that separating employment and working hour analyses allows for a better understanding of the differences in outcomes between treatment groups and potential consequences for individuals and public finances.

Beyond employment issues, scientists investigated whether increased working hours and income could generate additional income through income tax and help offset public healthcare expenditures. In Denmark, Ozempic treatment for diabetes is subsidized, whereas patients using Wegovy for weight control pay the full cost themselves.

According to the study's fiscal analysis, the additional income from income tax related to increased earned income among patients taking these drugs could help cover public expenses for subsidized diabetes treatment.

Raul Santaeulalia-Llopis, an economics lecturer at NYU Abu Dhabi, stated that medical procedures should not be evaluated solely on their clinical outcomes. He emphasized that evaluating only metrics such as weight loss or blood sugar levels overlooks the broader picture, requiring consideration of factors beyond direct medical costs.

He noted that the study shows that when changes in employment, working hours, and subsequent tax revenues are taken into account, the financial calculation changes drastically. Nevertheless, Santaeulalia-Llopis stressed that understanding the broader influence of these drugs requires studying whether they contribute to sustainable lifestyle changes.

He questioned whether GLP-1 is a catalyst for a healthier and self-sustaining lifestyle, or if its economic dividends merely create a new form of pharmaceutical dependence. Santaeulalia-Llopis reported that current research with the Abu Dhabi Department of Health under the Thiqa obesity program is focused on this question.

The findings were published as a discussion paper by the Center for Economic Policy Research (CEPR). By analyzing diabetes treatment and weight control separately, the researchers highlighted how the economic effects of semaglutide can vary depending on the patient's health status, employment status, and method of financing the treatment. The study also suggests that assessing the broader economic impact of such drugs can help policymakers better understand their potential consequences for public finances and healthcare spending.

Gynecologist from UAE spoke at summit on the biggest health threat of this century
Read more
www.khaleejtimes.com

Gynecologist from UAE spoke at summit on the biggest health threat of this century

According to research, by 2030, nearly one in five women worldwide is expected to face obesity, while among men, this figure is one of seven. Consequently, the topic of weight management has gained particular relevance.

During the opening of the Women's Summit by Gulf Times in Dubai on Wednesday, Dr. Bohaira El Geoushi, a consultant gynecologist and reproductive medicine specialist, used this fact to emphasize the pervasive danger posed by obesity and the importance of properly addressing this issue. She stated: 'Obesity is recognized as the biggest health threat of this century that can be acted upon.'

Dr. El Geoushi noted that obesity is a chronic condition requiring lifelong management, adding that excess weight may only be one of the visible changes. She stressed that 'timely and personalized care is crucial.'

In her words, obesity is just the tip of the iceberg, as it affects a person at all stages of life. It can lead to a range of health problems, including insulin resistance, polycystic ovary syndrome (PCOS), osteoporosis, high blood pressure, heart and bladder problems, dementia, and even cancer.

Dr. El Geoushi also pointed out that solving this problem must take into account many factors. She acknowledged the numerous roles and difficulties women face in daily life, whether at home or at work. She urged: 'We must be proactive in managing our own lives... we must fix this now.'

Despite presenting alarming data, Dr. El Geoushi offered useful recommendations. She believes that a helpful conversation about weight management should be respectful and include goal setting and practical plans. 'The dialogue should focus on improving women's daily lives.'

She also refuted the idea that weight loss is always a difficult task. Dr. El Geoushi observed that often losing 5–10% of body weight is sufficient. If going to the gym is not feasible, she recommended activities such as walking, Pilates, or yoga.

Popular